Emesis induced by cytotoxic agents is an important side effect that may determine a patient's acceptance of cancer chemotherapy and may be responsible for his defaulting from potentially effective treatment. Despite the availability of several antiemetic drugs, this complication is generally poorly controlled. Gralla et al found metoclopramide in high intravenous doses to be an effective antiemetic agent, better than placebo or prochlorperazine, in chemotherapy with cisplatin.' Maher reported the use of lorazepam in antiemetic premedication for cytotoxic treatment.2 We evaluated both these drugs in a crossover study of emesis induced by cisplatin and dacarbazine, two of the most highly emetic cytotoxics.
Patients, methods, and results
We studied 19 patients with disseminated malignant melanoma (nine men, 10 women, median age 52) requiring chemotherapy with the (B)DPV3 regimen.3 Only two patients had previously received a course of adjuvant vindesine chemotherapy and neither had experienced nausea or vomiting. No patients had cerebral metastases and all had a Kamofsky performance of >60%.
During the trial cisplatin was given in a standard dose of 60 mg by intravenous bolus injection with mannitol diuresis and hydration on day 1 of the cycle. Vinblastine and bleomycin were also given on day 1, and vindesine on day 2. Dacarbazine I g by intravenous bolus was given with vincristine on day 14. The cycle was repeated on day 28.
Patients were alternately allocated to receive either high dose metoclopramide or lorazepam during the first of two cytotoxic cycles and the alternative antiemetic for the second cycle. Despite the moderate dose of cisplatin used in this trial, the number of emetic episodes observed with metoclopramide was greater than that observed in an earlier report,' and is in agreement with the number described in a more recent communication." The study has also highlighted the variable reaction of patients to the side effects of chemotherapy. We think that the final arbiter of the toxicity of cancer treatment should be the patient, who can withdraw from it when it no longer constitutes treatment. 
